NXTC - NextCure, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
51.24
-0.31 (-0.60%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close51.55
Open51.34
Bid0.00 x 900
Ask0.00 x 1800
Day's Range49.65 - 52.36
52 Week Range13.86 - 109.00
Volume191,205
Avg. Volume484,192
Market Cap1.4B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.53
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est72.20
  • GlobeNewswire

    NextCure to Present at Piper Jaffray 31st Annual Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Piper Jaffray 31st Annual Healthcare Conference in New York on December 3, 2019 at 2:00 pm ET. A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Announces Closing of Public Offering

    BELTSVILLE, Md., Nov. 19, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • Benzinga

    The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...

  • GlobeNewswire

    NextCure Announces Pricing of Public Offering of Common Stock

    BELTSVILLE, Md., Nov. 14, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Announces Proposed Public Offering of Common Stock

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced a proposed public offering of 3,200,000 shares of its common stock. In addition, NextCure intends to grant the underwriters a 30-day option to purchase up to an additional 480,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the common stock to be sold in the offering will be offered by NextCure.

  • Benzinga

    Analyst Trims NextCure Price Target Following SITC Presentation, Still Sees Big Upside

    NextCure Inc (NASDAQ: NXTC) shares are settling down after the volatile run in the past few sessions. Alec Stranahan reiterated an Overweight rating price on NextCure and reduced the price target from $92 to $89. With the large unmet need for new immunotherapy approaches for cancer, the unique mechanism of action of NextCure's NC318 and NC410 is attractive, Stranahan said in a note.

  • GlobeNewswire

    NextCure Reports Third Quarter 2019 Financial Results

    BELTSVILLE, Md., Nov. 12, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • Barrons.com

    NextCure Stock Collapses After New Cancer Drug Data

    Shares of biotech firm NextCure were down 50% on Monday as new data on the company’s experimental cancer treatment tempered last week’s enthusiasm, when the company’s stock leapt nearly 250% in a single day.

  • Benzinga

    These Are The Winners Of The Inaugural WeTrader Paper Trading Competition

    The WeTrader Paper Trading Competition , a 5-week paper trading contest hosted by the zero-commission trading platform Webull, has officially ended. Here’s a look at how the 83 contestants—the top 10 portfolios ...

  • GlobeNewswire

    NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that updated clinical results from the Phase 1 portion of its ongoing trial with NC318, a monoclonal antibody targeting Siglec-15 (S15), were presented at the SITC annual meeting. In addition, NextCure announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial of NC318. The most common tumor types enrolled included: non-small cell lung cancer (NSCLC) (13 patients), ovarian cancer (seven patients), melanoma (seven patients), breast cancer (four patients) and colorectal cancer (three patients).

  • GlobeNewswire

    NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

    NextCure, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing next-generation immunomedicines for cancer and other immune-related diseases, today announced that the company will host and webcast an event with its Chief Medical Officer at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2019 at 6:30 p.m. Eastern Time at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. At the event, NextCure will discuss updated clinical results from the Phase 1 portion of its ongoing trial with NC318 that are being presented earlier in the day at SITC. Institutional investors and analysts are requested to rsvp to Drew Phillips at drew.phillips@westwicke.com or by phone at 443-213-0497.

  • InvestorPlace

    WeWork IPO was a Failure – These 2 IPO Stocks are Surging

    I always keep tabs on IPO stocks, as I'm a big believer in investing early, but I'll be the first to tell you that it's not always easy.If you're looking for large, long-term gains - and who isn't? - investing early is necessary. One example you probably know is Facebook (NASDAQ:FB). If you'd invested five years ago, you'd be richer today than if you'd just invested this year.But on the road to greatness, Facebook hit its share of roadblocks. In fact, the stock went absolutely nowhere for over a year after its IPO in 2012.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe market is full of stories like that. And IPO stocks don't always go on to do great things. Some of the most anticipated IPOs fizzle out before they even begin, as we recently saw with the whole WeWork debacle. * 7 Stocks to Buy in November In the space of just one month, the coworking office space company filed for an IPO, saw potential creditors flee once they got a look at its financials, yanked the IPO entirely, and ultimately fired its scandalous CEO, Adam Neumann. WeWork was once privately valued at $47 billion, but now that seems to have gone up in smoke.One big problem here is that once WeWork got into the spotlight, the hype - and the valuation - got out of control. I've seen it many times before, but sooner or later, the honeymoon ends and reality sets in. Put These Two IPO Stocks On Your Watch ListRight now, the best-performing IPO stocks are also the least talked-about, which is pretty telling. A couple stand out to me right now. They might not have a cool enough story to get on TV, but you'll definitely want to put them on your watch list all the same.InMode (NASDAQ:INMD) is a medical device company based in Israel. Specifically, its products are used in minimally invasive surgical and aesthetic procedures in the fields of dermatology, cellulite removal, and gynecology. It's a $1 billion company by market cap, was founded in 2008, and has been profitable for years. Financial buzz puts the sector InMode is going after, medical aesthetics, at $22.2 billion in five years.INMD stock is up 133% since its IPO this August. Even better, its sales are on a steady climb, too - from $53 million in 2017 to $187 million projected for 2020. That would be 253% sales growth in just three yearsThe other promising, under-the-radar IPO is NextCure (NASDAQ:NXTC). It's a clinical stage biotech focused on cancer treatments. The company is pretty small at a market cap of less than $600 million, but it has a deal with drug giant Eli Lilly (NYSE:LLY) that could result in up to $1.4 billion in milestone payments. The stock is up 30% since its IPO this May. Given the lucrative deal with Big Pharma, I wouldn't be surprised to see much better gains down the road.If you've never heard of either of these IPO stocks before, I wouldn't be surprised. They've been neglected by the media "hype machine"… and that's promising. It tells me that there's still a lot of potential for future gains - gains that these companies can earn the old fashioned way: by selling more product and delivering shareholder value, year after year.I'll be keeping an eye out for that. You should, too.Matthew McCall left Wall Street to actually help investors -- by getting them into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Buy-and-Hold Stocks to Play Investing's Biggest Trends * 7 Stocks to Buy in November * 5 Strong Buy Stocks Under $5 With Massive Upside Potential The post WeWork IPO was a Failure a€“ These 2 IPO Stocks are Surging appeared first on InvestorPlace.

  • GlobeNewswire

    NextCure Announces Promotion of Timothy Mayer, Ph.D., to Chief Operating Officer

    BELTSVILLE, Md., Oct. 02, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure to Present Clinical Data from NC318 Phase 1/2 Clinical Trial at 34th Annual Meeting of SITC

    BELTSVILLE, Md., Oct. 01, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure to Present at Morgan Stanley 17th Annual Global Healthcare Conference

    NextCure, Inc. (NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that the company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York on September 10, 2019 at 10:00 am ET. A live audio webcast will be available through the Events and Presentations page of the Investors section of the company’s website at www.nextcure.com. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.

  • GlobeNewswire

    NextCure Reports Second Quarter 2019 Financial Results

    BELTSVILLE, Md., Aug. 12, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?
    Simply Wall St.

    What Kind Of Shareholder Owns Most NextCure, Inc. (NASDAQ:NXTC) Stock?

    The big shareholder groups in NextCure, Inc. (NASDAQ:NXTC) have power over the company. Large companies usually have...

  • 2 Small-Cap Biotech IPOs You Should Know About
    Motley Fool

    2 Small-Cap Biotech IPOs You Should Know About

    The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.

  • GlobeNewswire

    NextCure Reports First Quarter 2019 Financial Results

    BELTSVILLE, Md., June 10, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • GlobeNewswire

    NextCure Announces Pricing of Initial Public Offering of Common Stock

    BELTSVILLE, Md., May 08, 2019 -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class.

  • Benzinga

    IPO Outlook For The Week: Uber (And 11 Others)

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Milestone Pharmaceuticals Inc. (MIST) will issue 5 million shares between ...